Are drug companies making good on their access promises?

Pharmaceutical companies have been good at making commitments to improve equitable access to medicines.

Through its 2022 accord, Pfizer pledged to make all of its medicines and vaccines available at not-for-profit prices in 45 lower-income countries. Sanofi has committed to accelerate affordable access to its products in “places where we can have the greatest impact.” And Eli Lilly has a long-standing commitment to improve access to health care for 30 million people annually.

The Access to Medicine Foundation wanted to know just what approaches these companies — and the 17 other leading pharmaceutical firms — have in place to determine how many patients are actually accessing their products.